Home » Newsletters » BioWorld Science

BioWorld Science

March 7, 2007

View Archived Issues

Shire rounds up 2006 highlights

Recent patents describe new therapeutic agents for endocrine-related disorders

Novel treatment options for metabolic disorders described in recent patents

AVE-8062 causes necrosis and reduces metabolic activity in ovarian tumors

HMMC-1 reduces lymph node tumor burden

Novel therapeutic agents for infectious diseases disclosed in recent patent literature

CDC study validates Lovaxin C treatable population

Positive data reported for TRA-8/cisplatin combo in a model of cervical cancer

Aker BioMarine and Pronova to establish new company

AD-923 begins U.S. phase I development for cancer breakthrough pain

GSK's prepandemic vaccine protects against different strains of H5N1

APD-125 begins phase II for insomnia

Lilly to acquire Hypnion

New company Calistoga closes Series A financing

Cerus receives grants to develop vaccines based on Listeria platforms

Positive findings from first stage of phase II LymphoSeek trial

InterMune discontinues phase III INSPIRE trial of Actimmune in IPF

Phase III studies of ferumoxytol cleared to continue to completion

BioCryst and Shionogi collaborate on injectable peramivir in Japan

D-4F, an apoA-I mimetic, shows efficacy in asthma model

Kyowa Hakko Kogyo licenses KW-2871 to Life Science Pharmaceuticals

E1-I.N.T. reduces HbA1c levels in type 1 and type 2 diabetes

MEM-1003 shows no efficacy in bipolar mania

Significant pain relief demonstrated in phase IIb study of Fentanyl TAIFUN

Positive findings for Collegium's seasonal allergic rhinitis combination product

PHX-1149 significantly improves postprandial glucose and HbA1c levels

HMOCC-2 monoclonal antibody shows potential to treat ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...